Bisphosphonate News and Research

RSS

Bisphosphonate is a drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone. Also called diphosphonate.

Vitamin D and calcium improves bone density in male veterans treated with AEDs

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs (AEDs).

8 Nov 2013

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

5 Oct 2013

Osteoporosis drug could provide effective pain relief to patients with osteoarthritis

St George's, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.

6 Sep 2013

Updated guidelines on diagnosis and management of osteoporosis published in Maturitas

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of the National Osteoporosis Guideline Group Update 2013 on diagnosis and management of osteoporosis in postmenopausal women and older men in the journal Maturitas.

20 Jun 2013

$Study: Primary medication nonadherence can lead to increased risk of bone fractures$

Study: Primary medication nonadherence can lead to increased risk of bone fractures

Nearly 30 percent of women failed to pick up their bisphosphonate prescriptions, a medication that is most commonly used to treat osteoporosis and similar bone diseases, according to a Kaiser Permanente study published this week in the journal Osteoporosis International.

19 Apr 2013

Research identifies important role of zinc in kidney stone formation

Kidney stones usually make their presence known suddenly, often sending a person to the hospital in excruciating pain. Each year in the U.S. more than a million people seek medical attention for kidney stones, technically called nephrolithiasis.

8 Apr 2013

Zometa does not prevent bone metastases

The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today.

20 Mar 2013

Medication use and doctor visits drive up jaw necrosis-related costs

Long-term medication use and follow-up visits are the main drivers affecting costs associated with cancer-related bisphosphonate-associated osteonecrosis of the jaw, report researchers in Oral Diseases.

8 Mar 2013

$Bisphosphonate link to nonhealing fractures strengthened$

Bisphosphonate link to nonhealing fractures strengthened

US scientists have identified a safety signal between bisphosphonate use and nonhealing femoral fractures, possibly due to the rare side effect, atypical femur fracture.

1 Mar 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

IAP antagonists may actually increase risk of bone tumors

Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.

14 Feb 2013

Aspirin improves colorectal cancer survival in tandem with gene mutation

Aspirin significantly improves survival in colorectal cancer patients who have a mutation in a carcinogenesis-associated signaling pathway, the results of a US and Japanese study indicate.

29 Oct 2012

Alendronate decreases BMD loss in prostate cancer

Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density in prostate cancer patients who start androgen-deprivation therapy, show study findings.

19 Sep 2012

Bisphosphonate benefit for breast cancer yet to be proven

Older patients with breast cancer may benefit from adjuvant treatment with oral bisphosphonates, but further studies are needed before general application in the breast cancer population, say researchers.

19 Jun 2012

$Bisphosphonate therapy may increase risk of atypical femoral fractures$

Bisphosphonate therapy may increase risk of atypical femoral fractures

Treatment with bisphosphonate therapy appears to be associated with an increased risk of atypical fractures of the femur, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

22 May 2012

NBHA commends FDA for continuing investigation of bisphosphonate treatment for osteoporosis

In response to today's Perspective pieces published in the New England Journal Of Medicine, the National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of its 42 members from the private and non-profit sectors to collectively advance bone health and prevent disease, commends the U.S. Food and Drug Administration (FDA) for continuing to investigate the risks and benefits of long-term bisphosphonate treatment.

11 May 2012

$Women with spine fractures can benefit from alendronate therapy$

Women with spine fractures can benefit from alendronate therapy

Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it. Based on available evidence, a UCSF researcher reevaluated his 2006 finding from a randomized 10-year study of alendronate, a type of bisphosphonate - a class of drugs that prevent loss of bone mass.

10 May 2012

Low bone density drugs may protect women from endometrial cancer

Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study at Henry Ford Hospital.

22 Mar 2012

Bisphosphonates improve fixation of dental impants in human bones

Millions of people have bad teeth replaced with implants. Often following the procedure, they are unable to chew food for up to six months, until the implant has become fixated in the bone. Now, for the first time, a drug coating that has been tested on humans allows titanium screws to adhere to the bone better and faster. The Link-ping researchers behind the method report that the results are good.

2 Mar 2012

$Bisphosphonates may raise risk of atypical femur fracture$

Bisphosphonates may raise risk of atypical femur fracture

There is growing evidence that supports an association between atypical fractures of the femur- a rare break of the thigh bone, typically without trauma - and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis.

9 Feb 2012